Cyclic derivative, preparation method therefor and use thereof
By designing cyclic derivatives to activate the M4 receptor, this study addresses the shortcomings of existing M4 receptor-targeting compounds in the treatment of schizophrenia, providing a new approach to treating the disease.
WO2026145797A1PCT designated stage Publication Date: 2026-07-09SHANGHAI JINGXIN BIOLOGICAL MEDICAL +1
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- SHANGHAI JINGXIN BIOLOGICAL MEDICAL
- Filing Date
- 2026-01-05
- Publication Date
- 2026-07-09
AI Technical Summary
Technical Problem
Existing compounds targeting the M4 muscarinic acetylcholine receptor are insufficient for the treatment of schizophrenia, necessitating the development of new M4 receptor agonists.
Method used
A cyclic derivative is provided, having the structural formula of a compound of formula I or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or stereoisomer thereof, which is designed to activate the M4 receptor through a specific combination and linkage of groups for the treatment of schizophrenia.
Benefits of technology
This cyclic derivative can effectively activate the M4 receptor and has the potential to treat schizophrenia, providing a new treatment option.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure PCTCN2026070668-APPB-I100001 
Figure PCTCN2026070668-APPB-I100002 
Figure PCTCN2026070668-APPB-I100003
Abstract
The present invention relates to a cyclic derivative, a preparation method therefor and the use thereof. The cyclic derivative can be used as a muscarinic acetylcholine receptor agonist and / or a Sigma receptor agonist, or can be used for treating schizophrenia, Parkinson's disease, Alzheimer's disease, depression and other neuropsychiatric diseases.
Need to check novelty before this filing date? Find Prior Art